Financial Analyst Summary: Sakar Healthcare Limited Regulatory Compliance and Financial Results
Company Response to Exchange Query
Date of Communication: May 23, 2026 (response to NSE email dated May 22, 2026)
Nature of Query: The National Stock Exchange of India Limited raised observations regarding the Financial Results submitted by the company.
Company's Clarification: The company clarified that they are submitting Financial Results incorporating "Standalone" and "Consolidated" in the heading of the respective Cash Flow Statements and Standalone Auditor's Report incorporating the place of signing. The company confirmed that there is no change in the financial figures, disclosures, and Auditor's Opinion submitted earlier to the Exchange.
Financial Results Details
Standalone Financial Results for Quarter Ended March 31, 2026 (Rs. in lakh):
- Revenue from operations: 7,109.70
- Other income: 17.12
- Total Income: 7,126.82
- Profit before tax: 1,806.00
- Tax expense:
- Current tax: 301.44
- Deferred tax: 80.62
- MAT credit (entitlement): 321.51
- Profit for the period: 1,102.43
- Total Comprehensive Income: 1,099.76
- Basic EPS: ₹4.96
- Diluted EPS: ₹4.96
Standalone Financial Results for Year Ended March 31, 2026 (Rs. in lakh):
- Revenue from operations: 25,173.60
- Other income: 228.74
- Total Income: 25,402.34
- Profit before tax: 3,975.52
- Tax expense:
- Current tax: 675.68
- Deferred tax: 304.11
- MAT credit (entitlement): (52.73)
- Profit for the period: 3,048.46
- Total Comprehensive Income: 3,037.77
- Basic EPS: ₹13.70
- Diluted EPS: ₹13.70
- Paid-up equity share capital: 2,224.99
- Reserves excluding Revaluation Reserves: 30,228.78
Consolidated Financial Results: The consolidated results are identical to standalone results since the subsidiary company (Sakar Oncology Private Limited) has not carried out any business transactions during the reporting period.
Key Financial Position (Standalone as at March 31, 2026):
- Total Assets: ₹48,109.45 lakh
- Total Equity: ₹32,453.77 lakh
- Total Liabilities: ₹15,655.67 lakh
- Non-current assets: ₹34,056.09 lakh
- Current assets: ₹14,053.36 lakh
- Inventories: ₹7,004.14 lakh
- Trade receivables: ₹5,008.33 lakh
- Cash and cash equivalents: ₹4.02 lakh
- Bank balances other than above: ₹21.75 lakh
Additional Corporate Actions
Auditor Appointments:
- Statutory Auditors: M/s. J. S. Shah & Co., Chartered Accountants (FRN: 132059W) provided unmodified opinion
- Secretarial Auditors: Appointed M/s. Kashyap R. Mehta & Partners, Company Secretaries, Ahmedabad (FRN: P2025GJ106000) to fill casual vacancy caused by resignation of M/s. Nishant Pandya & Associates
Business Segment: The company operates only in one segment - Manufacturing of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections.
Subsidiary: The company has one wholly owned subsidiary - Sakar Oncology Private Limited
Signatories:
- Bharat Soni, Company Secretary & Compliance Officer
- Sanjay S. Shah, Managing Director (DIN: 01515296)